Blood protein levels may reveal ICU patient prognosis
NCT ID NCT07414160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 500 critically ill adults in the ICU to see if changes in a blood protein called prealbumin can predict who will die or get infections. Researchers will track prealbumin levels over time and compare them to patient outcomes. No new treatment is given—participants receive standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better monitor nutrition in ICU patients and identify those at higher risk of poor outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. It may find no clear link between prealbumin changes and patient outcomes, or the results may not apply to all ICU patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients admitted to the ICU of Jilin University First Hospital.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. age \> 18 years, 2. SOFA score ≥ 2 3. at least three prealbumin data points within the previous 14 days. Exclusion Criteria: 1. patients with liver failure 2. patients with kidney failure, 3. hereditary amyloidosis and Alzheimer's disease 4. long-term use of hormones or NSAIDs. -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adult are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Part check may reveal hidden malnutrition in sickest kids
- Can a Dentist's toothbrush keep ICU patients healthier?
- Can a simple bedside panel make intensive care feel more human?
- AI that refreshes ICU death risk every 6 hours put to the test
- Can a peptide drug shield the hearts of ICU patients?
- Why do some ICU patients bleed in the gut? researchers map the risk